Benzinga | Jan 15, 2021 08:04AM EST

B of A Securities Downgrades Intercept Pharmaceuticals to Underperform

B of A Securities analyst Geoff Meacham downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Neutral to Underperform.